The integration of Leica Biosystems’ BOND RX into the GeoMx DSP workflow will enhance the overall sample processing workflow for translational research applications, such as biomarker discovery. These applications demand high throughput analysis on precious FFPE samples. GeoMx DSP is designed for throughput of up to 20 FFPE slides per day, and in combination with the Leica BOND RX, the workflow can be achieved with less hands-on time and increased consistency compared to a manual slide preparation workflow. This will enable translational researchers to identify spatially resolved biomarkers at a rapid pace.
Under the co-marketing agreement, Leica Biosystems can promote the GeoMx DSP and GeoMx assays to its BOND RX autostainer customers, with technical support and training provided by
“We have already used the BOND RX autostainer for many successful projects performed under our DSP Technology Access Program. Now that we are commercializing the GeoMx DSP, we want our customers to have access to the same automation and reproducibility that we have seen with the BOND RX. We look forward to introducing GeoMx DSP to every Leica BOND RX customer who seeks a high multiplex, RNA or protein, spatial profiling solution compatible with their FFPE tissue samples. With the BOND RX and GeoMx DSP’s compatible throughput, the two platforms together will provide an integrated and complete solution, and should become a workhorse for any spatial profiling researcher,” said
GeoMx Digital Spatial Profiling
GeoMx DSP enables high throughput multiplex spatial profiling of RNA and protein targets in a variety of sample types, including FFPE tissue sections. The full launch of the GeoMx DSP platform is scheduled to take place at the upcoming meeting of the American Association of Cancer Research (AACR) being held March 29-April 3, 2019, and over 30 systems have already been pre-ordered. At AACR 2019, over 15 posters will be presented at AACR featuring spatial applications using GeoMx DSP; 11 of the posters will be presented by customers, collaborators and GeoMx DSP beta sites.
About Leica Biosystems
Leica Biosystems is a global leader in workflow solutions and automation, striving to advance cancer diagnostics to improve patients’ lives. Leica Biosystems provides anatomic pathology laboratories and researchers a comprehensive product range for each step in the pathology process, from sample preparation and staining to imaging and reporting. Our easy-to-use and consistently reliable offerings help improve workflow efficiency and diagnostic confidence. The company is represented in over 100 countries. It has manufacturing facilities in 7 countries, sales and service organizations in 19 countries, and an international network of dealers. The company is headquartered in Nussloch,
About NanoString Technologies, Inc.
For more information, please visit www.nanostring.com.
Vice President, Investor Relations & Corporate Communications
Source: NanoString Technologies, Inc.